NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Xortx Therapeutics Inc. XRTX
3 fiscal years on record · CAD · FY2021 reported · SEC filings only
CAD -1.7M
CAD -6.1M
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
·
Revenue, FY2021 · full 3-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
·
ROE
Not applicable: equity was zero or negative in this period, so return on equity has no meaning.
Three returns, three denominators.
Return on equity-18.4%
Return on assets-13.6%
Return on capital employedNot available: we don't have a clean operating profit figure for this period.
Each CAD of equity lost 18 cents this year.
The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · CAD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue CAD B | ◌ | ◌ | ◌ |
| Operating income CAD B | ◌ | ◌ | ◌ |
| EBITDA CAD B | ◌ | ◌ | ◌ |
| Income tax CAD B | ◌ | ◌ | ◌ |
| Net income CAD B | −0.0 | −0.0 | −0.0 |
| Free cash flow CAD B | −0.0 | −0.0 | −0.0 |
| EPS, diluted CAD | 9847641.00 | 6664025.00 | 5359444.00 |
| Dividend / sh CAD | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — |
| ROE % | −18.4 | — | — |
| Shares out B | 0.00 | ◌ | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 3 failures in 10 reconciliationsAUDITED
No fiscal year had a computed check that closed clean. 26 checks were skipped: the balance sheet is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency3 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2019